Print

Galleon Pharmaceuticals, Inc. Reports Positive Results from Second Phase I Study of GAL-021 for Treatment of Respiratory Depression  
9/20/2012 10:24:35 AM

HORSHAM, Pa.--(BUSINESS WIRE)--Galleon Pharmaceuticals, a leader in the development of novel medicines to treat breathing control disorders, today announced that results from a second Phase I clinical study of its investigational drug GAL-021 confirmed previous findings that the drug has dose-dependent effects on respiration. The purpose of the new study was to evaluate higher doses of GAL-021 to determine an appropriate dose range for future studies, including an upcoming Phase I proof-of-concept study utilizing conditions simulating post-operative patients who have impaired respiration.
//-->